Eficlat50-BotMed-v1 is an EfficientNetB0-based image classification model fine-tuned to classify brain MRI scans into four categories: glioma, meningioma, no tumor, and pituitary tumor.
Model Details
Model Description
Eficlat50-BotMed-v1 is a transfer-learning model built on top of EfficientNetB0 (pretrained on ImageNet), fine-tuned for multi-class brain tumor classification from MRI images. It was trained on the Brain Tumor MRI Dataset using Google Colab GPUs, with a two-phase training strategy: an initial feature-extraction phase with the base model frozen, followed by a fine-tuning phase where the top ~30% of EfficientNetB0's layers were unfrozen and trained at a lower learning rate.
The model head consists of global average pooling, batch normalization, dropout, and two dense layers (256 and 128 units) before a final 4-way softmax classification layer. Data augmentation (rotation, translation, zoom, horizontal flip, contrast, and brightness jitter) was applied during training to improve generalization.
On a held-out test set of 1,600 images (400 per class), the model achieved 91% overall accuracy, with particularly strong performance on the "no tumor" and "pituitary" classes.
Intended for classifying brain MRI images into one of four categories: glioma, meningioma, no tumor, or pituitary tumor, for research, educational, and experimental purposes.
Downstream Use
Potential downstream applications include:
(1) research and educational tools for demonstrating transfer-learning-based medical image classification,
(2) a triage-assistance component in a larger clinical decision-support pipeline, always paired with review by a qualified radiologist or medical professional,
(3) a baseline model for benchmarking further fine-tuning, architecture changes, or dataset expansions, and
(4) integration into broader multi-modal medical AI systems (e.g. alongside BotMed's text-based medical chatbot models) as an image-understanding component.
Out-of-Scope Use
This model is not a certified diagnostic tool and must not be used as a substitute for professional radiological or medical evaluation. It is unsafe and inappropriate for any use where its output directly informs a real patient's diagnosis or treatment without review and confirmation by a licensed medical professional. It has not been validated for MRI scans outside the four trained classes, non-brain imaging, non-MRI modalities (e.g. CT, X-ray), or pediatric populations if not represented in the training data.
Bias, Risks, and Limitations
Class-specific error patterns: Per the confusion matrix, glioma and meningioma are the most frequently confused classes with each other and with pituitary (e.g. 34 glioma images misclassified as meningioma, 44 meningioma images misclassified as pituitary), while "no tumor" and "pituitary" are classified with very high accuracy. Users should be aware the model is comparatively weaker at distinguishing glioma and meningioma cases.
No clinical validation: Evaluation metrics (accuracy, precision, recall, F1, confusion matrix) measure performance against the dataset's own labels, not independent clinical ground truth. The model has not been evaluated by radiologists or validated against clinical diagnostic standards.
Dataset-driven bias: The training data is a compilation of three source datasets (Figshare, SARTAJ, and Br35H), which may carry inconsistencies in imaging equipment, patient demographics, acquisition protocols, and label quality across sources.
Limited class scope: The model can only classify into the four trained categories. Other tumor types, comorbidities, or abnormalities outside these categories will be forced into one of the four labels rather than flagged as "unknown."
Image quality sensitivity: As with most CNN-based image classifiers, performance may degrade on images with unusual orientations, low resolution, artifacts, or scanner types not well represented in training.
Recommendations
Users (both direct and downstream) should be made aware of the risks, biases, and limitations of the model. In particular:
Always pair model predictions with review by a qualified radiologist or medical professional before any clinical or patient-facing use.
Treat outputs as a research/assistive aid, not a diagnostic result.
Be aware of the model's comparatively higher error rate on glioma and meningioma classification.
Do not use this model on imaging modalities or patient populations not represented in its training data.
Trained on the Brain Tumor MRI Dataset (Kaggle, by Masoud Nickparvar), a combination of the Figshare, SARTAJ, and Br35H datasets. The dataset is organized into four classes — glioma, meningioma, no tumor, and pituitary — split into pre-defined Training and Testing directories.
Training Procedure
Trained on Google Colab GPUs using a two-phase transfer learning approach on top of EfficientNetB0 (ImageNet-pretrained).
Preprocessing
Images were resized to 224x224 and used at their raw pixel scale (0-255) without manual rescaling, since EfficientNetB0 handles input preprocessing internally.
Training regime: Standard float32 training (no mixed precision)
Batch size: 32
Image size: 224 x 224
Phase 1 (feature extraction): base model frozen, Adam optimizer (learning rate 0.001), up to 10 epochs
Phase 2 (fine-tuning): top ~30% of EfficientNetB0 layers unfrozen, Adam optimizer (learning rate 1e-4), up to 20 epochs
Loss: categorical crossentropy
Callbacks:ModelCheckpoint (best val_loss), EarlyStopping (patience 5 in phase 1, 7 in phase 2, restores best weights), ReduceLROnPlateau (factor 0.5, patience 3, min LR 1e-7)
Validation split: 20% of the Training directory held out for validation
Experiment tracking: Weights & Biases (wandb)
Speeds, Sizes, Times
Final logged training run metrics reached approximately 98.3% training accuracy and 100% validation accuracy by the end of fine-tuning (phase 2), before evaluation was run on the separate held-out test set (see Results below for true test performance).
The Testing split of the Brain Tumor MRI Dataset, evaluated on a balanced held-out set of 1,600 images (400 per class). Full evaluation artifacts are available in the evaluation folder.
Factors
Evaluation was disaggregated by the four tumor classes (glioma, meningioma, no tumor, pituitary); no other subpopulation breakdown was performed.
Metrics
Accuracy — overall proportion of correctly classified images.
The model achieves 91% overall accuracy on the held-out test set. "No tumor" and "pituitary" classes are classified with the highest recall (0.99 and 1.00 respectively), while glioma and meningioma show comparatively lower recall (0.82 each), with most of the confusion occurring between glioma, meningioma, and pituitary classes. Precision is consistently high (0.88-0.93) across all classes, indicating relatively few false positives per predicted class.
Example Outputs
Example inference output on a sample MRI image is available here: inferencing.png.
EfficientNetB0 backbone (ImageNet-pretrained) with a custom classification head (GlobalAveragePooling2D, BatchNormalization, Dropout, Dense(256), BatchNormalization, Dropout, Dense(128), Dropout, Dense(4, softmax)), fine-tuned in two phases for 4-class brain tumor classification from MRI images.
Compute Infrastructure
Google Colab
Hardware
Google Colab GPU instance(s).
Software
TensorFlow, Keras 3, scikit-learn, Weights & Biases, Google Colab.
